Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026

Allarity Therapeutics announced it will present a Trial-in-Progress poster on its Phase 2 stenoparib trial at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen. The poster will outline the study design and clinical rationale for evaluating stenoparib, a dual PARP and WNT pathway inhibitor, in patients with advanced platinum-resistant or platinum-ineligible ovarian cancer. The presentation will be led by Principal Investigator Dr. Kathleen N. Moore, a leading expert in gynecologic oncology.

06/18/2026, 8:00 AM • GlobeNewswire

PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Over 25 pharmaceutical companies are actively developing 30+ PARP inhibitor drugs in clinical trials, with major players including AstraZeneca, Gilead Sciences, and Nerviano Medical Sciences advancing promising candidates like Saruparib and NMS-293. The pipeline shows robust activity across multiple cancer indications including breast cancer, prostate cancer, and glioblastoma, with approximately 12+ drugs in early to mid-stage development. Recent developments include clinical collaborations and first-in-human trial updates from companies like Acerand Therapeutics and Synnovation Therapeutics.

05/07/2026, 1:00 PM • GlobeNewswire

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics announced that the US Patent and Trademark Office has issued a Notice of Allowance for its stenoparib DRP® companion diagnostic patent application. The patent, expected to be formally granted within three months, would provide exclusivity for stenoparib when used with the DRP test at least through 2039. The allowed claims cover methods for predicting clinical benefit and selecting patients most likely to benefit from stenoparib treatment.

04/27/2026, 8:00 AM • GlobeNewswire

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Allarity Therapeutics closed a $20 million non-convertible debt financing with Streeterville Capital to fund Phase 2 ovarian cancer trial completion and advance stenoparib toward FDA approval and commercialization. The financing extends the company's cash runway into mid-2028 and supports preparation for pivotal development and regulatory meetings.

03/06/2026, 8:00 AM • GlobeNewswire

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

Allarity Therapeutics announced that enrollment is now open for a Phase 2 clinical trial evaluating the combination of stenoparib and temozolomide for treating recurrent small cell lung cancer. The trial is conducted in collaboration with the U.S. Department of Veterans Affairs and fully funded through the VA's Special Emphasis Panel on Precision Oncology. The study will assess safety and efficacy at 11 VA sites across the US, with stenoparib's favorable safety profile potentially addressing toxicity limitations seen with previous PARP inhibitor combinations.

02/03/2026, 8:00 AM • GlobeNewswire

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

Allarity Therapeutics reported significant progress with stenoparib, receiving FDA Fast Track designation for advanced ovarian cancer and presenting clinical trial data showing median overall survival exceeding 25 months for patients receiving the drug twice daily.

11/14/2025, 9:00 AM • GlobeNewswire

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

Allarity Therapeutics presented promising Phase 2 clinical trial data for stenoparib, a dual PARP and WNT pathway inhibitor for advanced ovarian cancer. The study showed median overall survival exceeding 25 months, with potential benefits for patients with different genetic backgrounds.

09/22/2025, 8:00 AM • GlobeNewswire

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025

Allarity Therapeutics' CEO Thomas Jensen will present at the Biomarkers & Precision Medicine 2025 conference in London, discussing stenoparib, a novel dual PARP and WNT pathway inhibitor for cancer treatment, and the company's DRP® companion diagnostic platform.

09/17/2025, 8:00 AM • GlobeNewswire

Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

Allarity Therapeutics signed a non-exclusive licensing agreement with an undisclosed EU-based biotechnology company, providing access to proprietary DRP® algorithms in breast cancer and laboratory services, which validates their drug response prediction technology.

07/15/2025, 8:00 AM • GlobeNewswire

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

Allarity Therapeutics announced the appointment of Jeff Ervin as its new Chief Financial Officer, succeeding Alexander Epshinsky. Ervin brings nearly two decades of executive leadership experience in healthcare and biotech sectors, and will support the company's clinical development of stenoparib, a cancer treatment drug.

07/07/2025, 8:00 AM • GlobeNewswire

Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic

Allarity Therapeutics received patent acceptance in Australia for its Stenoparib DRP® companion diagnostic, marking a key step in protecting its proprietary drug response prediction technology for personalized cancer treatment.

06/30/2025, 8:00 AM • GlobeNewswire

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

Allarity Therapeutics has dosed the second patient in a Phase 2 clinical trial evaluating stenoparib, a dual PARP and WNT pathway inhibitor, for patients with advanced, recurrent, platinum-resistant ovarian cancer.

06/27/2025, 8:00 AM • GlobeNewswire